T22-PE24-H6 therapy would be appropriate for the 50% of AML patient candidates whose leukemic cells overexpress CXCR4, a feature that confers a poor prognosis and higher relapse rate [12,14,16,18]. Here, CXCR4 is linked to acute myeloid leukemia.